DKK635.90
2.14% day before yesterday
Copenhagen, Dec 27, 04:59 pm CET
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Novo Nordisk Stock price

DKK635.90
-107.50 14.46% 1M
-366.70 36.57% 6M
-62.20 8.91% YTD
-56.10 8.11% 1Y
+271.85 74.67% 3Y
+440.18 224.89% 5Y
+503.65 380.83% 10Y
Copenhagen, Closing price Fri, Dec 27 2024
+13.30 2.14%
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Key metrics

Market capitalization DKK2.81t
Enterprise Value DKK2.79t
P/E (TTM) P/E ratio 29.93
EV/FCF (TTM) EV/FCF 35.87
EV/Sales (TTM) EV/Sales 10.31
P/S ratio (TTM) P/S ratio 10.37
P/B ratio (TTM) P/B ratio 23.29
Dividend yield 1.48%
Last dividend (FY23) DKK9.40
Revenue growth (TTM) Revenue growth 26.15%
Revenue (TTM) Revenue DKK270.58b
EBIT (operating result TTM) EBIT DKK118.63b
Free Cash Flow (TTM) Free Cash Flow DKK77.75b
Cash position DKK74.88b
EPS (TTM) EPS DKK21.25
P/E forward 28.26
P/S forward 9.80
EV/Sales forward 9.73
Show more

Is Novo Nordisk a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Novo Nordisk Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

21x Buy
68%
6x Hold
19%
4x Sell
13%

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

Buy
68%
Hold
19%
Sell
13%

Financial data from Novo Nordisk

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
270,583 270,583
26% 26%
100%
- Direct Costs 41,512 41,512
22% 22%
15%
229,071 229,071
27% 27%
85%
- Selling and Administrative Expenses 48,821 48,821
2% 2%
18%
- Research and Development Expense 44,720 44,720
49% 49%
17%
135,530 135,530
34% 34%
50%
- Depreciation and Amortization 16,901 16,901
100% 100%
6%
EBIT (Operating Income) EBIT 118,629 118,629
28% 28%
44%
Net Profit 94,721 94,721
26% 26%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Novo Nordisk directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novo Nordisk Stock News

AD HOC NEWS
6 days ago
Die Aktien von Novo Nordisk DK0062498333 und Gerresheimer DE000A0LD6E6 haben sich am Montag von ihrem Kursrutsch vor dem Wochenende erholt.
AD HOC NEWS
9 days ago
Enttäuschende Studienergebnisse zum Abnehmmedikament Cagrisema haben dem dänischen Pharmakonzern Novo Nordisk DK0062498333 am Freitag ein historisch hohen Kursverlust eingebrockt.

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Head office Denmark
CEO Lars Jørgensen
Employees 63,370
Founded 1931
Website www.novonordisk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today